ReviewCancer cell international2025
Biology of stem cell paradox: a double-edged sword-implications for cancer therapy.
Review in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrating multi-omics data for next-generation cancer research and precision medicine.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Cancer Stemness and Dedifferentiation in Anaplastic Thyroid Carcinoma: Insights into a Multigenic, Microenvironmental Network and the Role of CD44.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This comprehensive review investigates the complex interactions between oncogenesis and stem cells, underscoring the crucial importance of cancer stem cells (CSCs) in the mechanisms of tumorigenesis, metastatic dissemination, and resistance to therapeutic interventions. CSCs constitute a distinct subset within neoplasms, defined by unique characteristics such as the ability to self-renew, the potential to differentiate into various cellular phenotypes, and an inherent resistance to conventional treatment strategies. It is hypothesized that these properties are regulated by a multitude of signaling pathways, including Wnt/β-catenin, Notch, and Hedgehog signaling cascades. The tumor microenvironment (TME) significantly influences CSC dynamics by providing a nurturing niche that enhances CSC survival, enables immune evasion, and contributes to resistance against therapies. Key components of the TME, such as cancer-associated fibroblasts and immune-modulating exosomes, play a crucial role in augmenting CSC plasticity and metastatic capabilities. Furthermore, the hypoxic environment prevalent within the TME enhances CSC stemness through both metabolic and epigenetic alterations. Despite the existence of promising CSC-targeted therapeutic strategies, including immunotherapy, small-molecule inhibitors, and combinatorial approaches, notable challenges persist. These obstacles include CSC plasticity and heterogeneity, as well as the potential for immune rejection of CSC-targeted therapies. Advancements in precision medicine, genomics, and novel therapeutic interventions instill hope for the improvement of CSC-targeted strategies. A comprehensive understanding of the fluid interactions between CSCs, standard stem cells, and the TME is vital for advancing personalized cancer treatments that enhance patient success and reduce recurrence rates. This review highlights the need for continued research to bridge existing knowledge gaps and facilitate the translation of foundational scientific discoveries into clinical practices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.